Central serous retinopathy (also called central serous chorioretinopathy, or CSCR) happens when fluid seeps under the retina—most often beneath the macula, the part of the eye responsible for sharp, detailed vision. This pocket of fluid creates a small “blister” that can make central vision look blurred, dim, distorted or smaller than it should. It can affect one or both eyes, and while it often settles on its own, it sometimes lingers or returns.
This article explains what causes CSR, who is most at risk, and the symptoms to watch for. You’ll learn how it’s diagnosed (including OCT scans and angiography), when simple observation is appropriate, and the treatment options used if fluid persists or recurs. We’ll also cover day‑to‑day management, medications to review, long‑term outlook, and when to seek urgent care.
How CSR affects the macula and central vision
In central serous retinopathy, fluid leaks from the choroid through a weak point in the retinal pigment epithelium (RPE) and collects under the macula. This creates a small serous detachment that lifts the light‑sensing cells off their support layer. The result is disrupted photoreceptor alignment and signalling, so fine detail and contrast drop and central vision becomes unreliable.
Because the macula drives sharp, colour‑rich sight, even a thin pocket of fluid can cause pronounced effects: straight lines may appear bent (metamorphopsia), objects can look smaller or further away (micropsia), colours seem dull, and a grey or dark spot can fade the centre. Vision may fluctuate as the fluid shifts, and early changes are often more obvious when one eye is covered.
Who is most at risk
CSR is most common in men aged 30–50 and in people under high stress or with “type A” traits. Risk rises with current or recent corticosteroid use (tablets, creams, inhalers or injections), obstructive sleep apnoea, hypertension, pregnancy, autoimmune disease (such as lupus), and use of phosphodiesterase‑5 inhibitors (Viagra, Cialis, Levitra). It can occur in women and older adults too, and may recur, so anyone with these risks and new central blur should be assessed.
Symptoms to watch for
CSR is usually painless and may affect one or both eyes. Symptoms can be subtle and fluctuate from day to day, often becoming most obvious when you cover the unaffected eye. Some people have no symptoms at all and the condition is only found on routine eye imaging.
- Blurred or dim central vision—like a smudge in the centre
- A dark or grey central spot that obscures detail
- Straight lines appear bent or wavy (metamorphopsia)
- Objects look smaller or further away than they are (micropsia)
- Colours—especially whites—look duller or washed out
Causes and risk factors you can change
CSR isn’t caused by one thing, but several exposures raise risk — many are modifiable. The biggest is stress and high cortisol; others relate to medicines and systemic health. Work with your GP and eye specialist to reduce the following where safe.
- Corticosteroids (tablets, creams, inhalers, injections): avoid or taper if possible.
- High stress/cortisol: prioritise stress reduction and adequate sleep.
- Obstructive sleep apnoea or insomnia: get assessed and treated.
- High blood pressure: monitor regularly and manage to target.
- PDE‑5 inhibitors and some decongestants: review necessity, dose and timing.
How CSR is diagnosed (OCT and angiography)
Diagnosis starts with a dilated retinal examination by an ophthalmologist, followed by imaging to confirm fluid under the macula and locate any leakage points. The first-line test is optical coherence tomography (OCT), a quick, non‑invasive scan that delivers cross‑sectional, 3D images of the retina, showing a serous detachment, subretinal fluid and any retinal pigment epithelium (RPE) changes. To map and characterise leakage, fluorescein angiography (IVFA) is often used: a dye injected into a vein travels to the eye, and sequential photographs highlight abnormal leakage patterns typical of central serous retinopathy. In chronic or atypical cases, indocyanine green angiography (ICG) may be added to assess the choroid and help exclude other causes. These scans also provide a baseline to monitor resolution over time.
- OCT: Confirms subretinal fluid, measures retinal thickness and RPE changes.
- Fluorescein angiography (IVFA): Identifies active leakage sites.
- ICG angiography (selective): Evaluates choroidal circulation in persistent/atypical cases.
Observation versus treatment: what to expect in the first 1–4 months
For most people with central serous retinopathy, the first step is observation. Because the fluid often drains on its own, many cases settle within 1–4 months without active treatment. During this watch‑and‑wait phase, your ophthalmologist will check vision and repeat OCT scans to confirm the pocket of fluid is shrinking. At the same time, modifiable risks—especially recent or ongoing corticosteroids and high stress—are addressed, and symptoms are monitored. If vision is significantly impaired or the fluid isn’t improving, earlier intervention is considered.
- Monitoring: Regular reviews with OCT to track fluid and macular thickness.
- Medication review: Steroids, PDE‑5 inhibitors and decongestants assessed with your GP.
- Lifestyle focus: Sleep, stress reduction and blood pressure control.
Treatment options for persistent or recurrent CSR
If CSR hasn’t improved after a few months, is severely affecting vision, or keeps returning, treatment can speed fluid resolution and lower the risk of permanent change. The choice depends on leak location, duration and proximity to the fovea. Your ophthalmologist will discuss benefits, risks and expected recovery for each option.
- Photodynamic therapy (PDT): Verteporfin “cold laser” closes leakage and is effective for chronic or recurrent CSR.
- Focal thermal laser: For leaks away from the fovea, a heated laser can seal them; it’s avoided near central vision.
- Micropulse laser: Low‑energy pulses may aid RPE repair with less collateral damage in selected cases.
- Medications: Some clinicians trial oral diuretics in selected cases. Anti‑VEGF injections are reserved if abnormal new vessels develop.
Medications to review or avoid
Some medicines can trigger or prolong central serous retinopathy by raising cortisol or affecting choroidal blood flow. Don’t stop prescribed drugs yourself—discuss changes with your GP, prescriber and ophthalmologist so benefits, risks and alternatives are balanced.
- Corticosteroids (any route): tablets, creams, inhalers or injections (including epidurals) are strongly linked—avoid or taper if safe.
- Phosphodiesterase‑5 inhibitors: erectile dysfunction medicines (e.g. sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra) may worsen CSR; consider pausing or alternatives.
- Decongestants (sympathomimetics): medicines for nasal congestion (e.g. pseudoephedrine/phenylephrine) can be contributory; review necessity, dose and timing.
Managing CSR day to day: stress, sleep and self‑monitoring (Amsler grid)
Day-to-day choices can lower cortisol, support healing and help you catch changes early. Prioritise 7+ hours of quality sleep, seek assessment if you snore or may have sleep apnoea, and build simple stress‑management into your routine. At home, monitor central vision with an Amsler grid and keep brief notes of any distortion. If a new dark spot appears, lines worsen or vision drops suddenly, contact your ophthalmologist promptly.
- Use an Amsler grid daily: Wear your normal glasses, cover one eye, hold the grid at reading distance, fixate the centre dot and note any wavy lines, missing or grey areas; repeat with the other eye and record the date.
- Reduce stress load: Schedule 10–20 minutes of exercise, breathing or meditation daily; protect downtime and limit high‑stress stimulants.
- Improve sleep habits: Keep consistent bed/wake times and limit late caffeine and alcohol; discuss suspected sleep apnoea with your GP.
- Track your health: Monitor blood pressure to target levels and bring your Amsler notes to reviews.
Prognosis, recurrence and complications
The outlook for central serous retinopathy is generally good. Most episodes resolve over weeks to a few months, with central vision improving as the fluid clears. However, some people notice lingering subtle changes—slight distortion, reduced contrast or colour desaturation—even after the retina looks dry on scans.
- Recurrence: Around half of patients will have CSR return, in the same or the other eye. Ongoing stress or corticosteroid exposure raises the risk.
- Chronic disease: Fluid that persists beyond 3–4 months increases the chance of lasting RPE/macular changes and usually warrants treatment.
- Complications (uncommon): RPE atrophy, macular thinning and choroidal neovascular membrane, which may require targeted therapy.
- Follow‑up: Regular reviews with OCT are important to confirm resolution and detect relapse early.
When to seek care urgently
CSR is usually painless and monitored, but rapid assessment can prevent missed diagnoses and protect the macula. Seek urgent care if vision changes suddenly or markedly in either eye, especially while using corticosteroids or other high‑risk medicines.
- Sudden central blur, new dark/grey spot, or rapidly worsening distortion
- Marked vision drop in your only good eye or in both eyes
- New symptoms soon after starting corticosteroids or PDE‑5 inhibitors (ED medicines)
Care and appointments at Bright Sight Eye Specialists (Sydney)
Based in Randwick, Bright Sight Eye Specialists is led by Moorfields‑trained retinal surgeon Dr Rahul Dubey. We diagnose and manage central serous retinopathy with precision imaging and tailored care, from careful observation to evidence‑based treatments (including laser or photodynamic therapy where appropriate). Expect timely appointments, clear communication, and transparent, upfront fees. We work closely with your GP and optometrist to review medications that may be driving CSR, and we support patients across Sydney’s Eastern Suburbs and from rural communities.
- At your visit: Dilated retinal exam and same‑day OCT
- If needed: Angiography arranged promptly
- Plan: Medication review plus a personalised observation or treatment pathway
- Follow‑up: Scheduled OCT monitoring and Amsler grid guidance
Your next steps
If you’ve noticed the symptoms we’ve described, don’t panic—most cases settle within weeks—but act sensibly now to protect your macula. Monitor with an Amsler grid, avoid new steroid exposure without medical advice, and arrange a prompt eye assessment so we can confirm the diagnosis and guide observation or treatment.
- Note your symptoms and any Amsler changes, including dates.
- List current medicines (especially steroids, decongestants, ED tablets) to review with your GP.
- Book a same‑day OCT assessment where possible—contact Bright Sight Eye Specialists to plan the right next step for you.